Department of Hematology, Zhongda Hospital, Medical School of Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA 17033, U.S.A.
Biosci Rep. 2020 May 29;40(5). doi: 10.1042/BSR20200008.
CD37, a member of the transmembrane 4 superfamilies (TM4SF), has been proved to be abnormally expressed in a range of malignancies. Herein, we investigate the effects of CD37 expression and analyze its clinical outcome in acute myeloid leukemia (AML) patients.
The RNA-seq and clinical data of AML patients were obtained from cBioPortal database. CD37 correlated genes, the expression prolife and survival curve of eight key genes were acquired from Gene Expression Profiling Interactive Analysis (GEPIA) and UALCAN. Pathway enrichment and protein-protein interaction (PPI) network analysis were performed based on metascape databases.
Our results showed that CD37 mRNA expression level was significantly up-regulated in patients with AML compared with healthy persons. Patients with high CD37 expression had shorter overall survival (OS) and disease-free survival (DFS). Pathway analysis data showed that CD37 is involved in DNA replication, RNA transport, Salmonella infection, ribonucleoprotein complex biogenesis, cell cycle phase transition and so on. Furthermore, we found eight genes correlated with CD37 are all highly expressed in AML patients, and high expression is associated with poor prognosis.
Our study described systematical expression profiles and the prognostic values of CD37 in AML; our data suggested CD37 might be novel therapeutic target and promising prognostic biomarker in the patients.
CD37 是跨膜 4 超家族（TM4SF）的成员，已被证明在多种恶性肿瘤中异常表达。在此，我们研究了 CD37 表达的影响，并分析了其在急性髓系白血病（AML）患者中的临床预后。
从 cBioPortal 数据库获取 AML 患者的 RNA-seq 和临床数据。从 Gene Expression Profiling Interactive Analysis（GEPIA）和 UALCAN 获取 CD37 相关基因、八个关键基因的表达谱和生存曲线。基于 metabascape 数据库进行通路富集和蛋白质-蛋白质相互作用（PPI）网络分析。
我们的结果表明，与健康人相比，AML 患者的 CD37 mRNA 表达水平显著上调。CD37 高表达的患者总生存期（OS）和无病生存期（DFS）更短。通路分析数据表明，CD37 参与 DNA 复制、RNA 转运、沙门氏菌感染、核糖核蛋白复合物生物发生、细胞周期相转变等过程。此外，我们发现与 CD37 相关的八个基因在 AML 患者中均呈高表达，且高表达与预后不良相关。
本研究描述了 CD37 在 AML 中的系统表达谱和预后价值；我们的数据表明 CD37 可能是 AML 患者的新治疗靶点和有前途的预后生物标志物。
